Company intelligence / Profile preview

Best Vascular

Atlanta, Georgia, United Statesbestvascular.com ↗

Ownership: Private
Development stage: Commercial

Overview

The Novoste™ Beta-Cath™ System by Best Vascular/Novoste was FDA-approved in November 2000 for treating in-stent coronary artery restenosis. It remains commercially available and considered standard of care for this indication. The company continues to support and expand clinical uses of vascular brachytherapy and has initiated trials for peripheral arterial disease and dialysis graft stenosis.

Therapeutic areas: Cardiovascular
Modalities: DeviceRadiopharmaceutical
Industry: Therapeutic Medical Devices

Drug pipeline

1 asset

Beta-Cath

Commercial

Indications: Coronary artery restenosis

Partnerships

Collaborations with Scripps Clinic, Emory University Hospital during development phase

Beyond the preview

Go deeper on Best Vascular.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Best Vascular.

Explore the full profile